Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Mii Amo. Douglas Friedman . Nestled within the awe-inspiring red rocks of Sedona, Arizona, Mii amo is a world-renowned ...

The robot has provided surgeons with instruments that offer a greater range of movement than in conventional keyhole surgery State-of-the-art robotic surgery has helped improve treatment for ...

The U.S. Food and Drug Administration has allowed the expanded use of Johnson & Johnson's drug, Tremfya, to treat adults with ...

US FDA grants rare paediatric disease designation to Cartesian Therapeutics’ Descartes-08 to treat juvenile dermatomyositis: Gaithersburg, Maryland Tuesday, September 10, 2024, ...

Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease ...

Cartesian Therapeutics, Inc. (RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, ...

Cartesian Therapeutics said it has received rare pediatric disease designation from the U.S. Food and Drug Administration for its Descartes-08 treatment of juvenile dermatomyositis.

IND filing for Phase 2 pediatric basket study on track for year-endGAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company ...

Brepocitinib tosylate is a small molecule commercialized by Roivant Sciences, with a leading Phase III program in Dermatomyositis.